Cancer awareness at the gynecologist: BRCA mutation

Sibirskaya E.V.; Sharoyan Zh.V.; Melkova K.N.; Melek I.K.

doi:https://doi.org/10.17116/repro20202604159

Close metadata

Recommended articles:

Quality of life after prophylactic mastectomy with simultaneous reconstruction. Plastic Surgery and Aesthetic Medicine. 2025;(2-2):5-12

Abstract:

Today breast cancer is the problem, which cannot be ignored. Each 8th woman faces this diagnosis during her life. Mostly women do not have a family history of cancer. However from 15 to 20% of breast cancer is associated with an inherited genetic mutation. Hereditary cancer usually affects young reproductive age women (15—49 years old). Moreover in case of genetic mutation person has increase risk of other types of cancer throughout their lives, including cancer of the ovaries and fallopian tubes. Detection of mutation carriers make the necessary to develope individual preventive programs, change cancer screening programm, modify treatment of already developed tumors. The frequent requirement of expensive sequencing of genes leads to the fact that in most countries of the world there are no state programs for identifying healthy mutation carriers and specialized centers for their observation. In this light, gynecologists are one of the most doctors doctors in the lives of healthy women with a BRCA mutation.

Keywords:

BRCA

BRCA carries

hereditary cancer

family cancer

cancer awareness

prophylactic mastectomy

prophylactic salpingectomy

Authors:

Sibirskaya E.V.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov;
Morozovskaya Children’s City Clinical Hospital of the Moscow Department of Health;
Pirogov Russian National Research Medical University

SPIN RSCI: 1356-9252
ORCID: 0000-0002-4540-6341

Sharoyan Zh.V.

LLC «Guide to health» outpatient clinic 12

Melkova K.N.

LLC «Guide to health» outpatient clinic 12

Melek I.K.

LLC «Guide to health» outpatient clinic 12

Received:

13.03.2020

Accepted:

21.05.2020

Close metadata

References:

Gamudi D, Blundell R. Tumor Suppressor Genes. Research Journal of Medical Sciences. 2010;4(4):280-284. https://doi.org/10.3923/rjmsci.2010.280.284
Melkova KN, Sharoyan ZhV, Frolov GP. Natural killers: license to kill. Klinicheskaya onkogematologiya. 2020;13:241-251. (In Russ.).
Cheent K, Khakoo SI. Natural killer cells: integrating diversity with function. Immunology. 2009;126(4):449-457. https://doi.org/10.1111/j.1365-2567.2009.03045.x
Hall J, Lee M, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250(4988):1684-1689. https://doi.org/10.1126/science.2270482
Ormiston W. Hereditary breast cancer. European Journal of Cancer Care. 1996;5(1):13-20. https://doi.org/10.1111/j.1365-2354.1996.tb00200.x
Gowen L, Johnson B, Latour AM, Sulik KK, Koller BH. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nature Genetics. 1996;12:191-194. https://doi.org/10.1038/ng0296-191
Lyubchenko LN, Bateneva EI. Mediko-geneticheskoe konsul’tirovanie i DNK-diagnostika pri nasledstvennoǐ predraspolozhennosti k raku molochnoǐ zhelezy i raku yaichnikov. Posobie dlya vrachej. M.: IG RONC; 2014. (In Russ.).
Petrucelli N, Daly M, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020.
Kuchenbaecker K, HopperJ, Barnes D, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC; BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Risks of breast, ovarian and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402. https://doi.org/10.1001/jama.2017.7112
Szabo C, King M. Population genetics of BRCA1 and BRCA2. American Journal of Human Genetics. 1997;60(5):1013.
Antoniou A, Pharoah P, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics. 2003;72(5):1117. https://doi.org/10.1086/375033
Judkins T, Rosenthal E, Arnell C, Burbidge LA, Geary W, Barrus T, Schoenberger J, Trost J, Wenstrup RJ, Roa BB. Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer. 2012; 118(21):5210. https://doi.org/10.`1002/cncr.27556
McClain M, Palomaki G, Nathanson K, Haddow J. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genetics in Medicine. 2005;7(1):28. https://doi.org/10.1097/01.gim.0000151155.36470.ff
Roa B, Boyd A, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics. 1996;14(2):185. https://doi.org/10.1038/ng1096-185
Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Research and Treatment. 2015;149(1):223-227. https://doi.org/10.1007/s10549-014-3218-x
Bateneva EI, Meshcheryakov AA, Lyubchenko LN, Kadochnikova VV, Panyshev LA, Trofimov DYu, Rebrikov DV. The frequency of eleven mutations of the BRCA1 and BRCA2 genes in an unselected sample of Russian breast cancer patients. Ural’skiǐ medicinskiǐ zhurnal. 2011;3(81):69-73. (In Russ.).
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. 2015;17(5):405-424. https://doi.org/10.1038/gim.2015.30
Mighton C, Charames G, Wang M, Zakoor KR, Wong A, Shickh S, Watkins N, Lebo MS, Bombard Y, Lerner-Ellis J. Variant classification changes over time in BRCA1 and BRCA2. Genetics in Medicine. 2019;21(10):2248. https://doi.org/10.1038/s41436-019-0493-2
Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New England Journal of Medicine. 1999;340(2):77-84. https://doi.org/10.1056/NEJM199901143400201
Skytte A, Crüger D, Gerster M, Laenkholm AV, Lang C, Brøndum-Nielsen K, Andersen MK, Sunde L, Kølvraa S, Gerdes AM. Breast cancer after bilateral risk-reducing mastectomy. Clinical Genetics. 2011;79(5):431-437. https://doi.org/10.1111/j.1399-0004.2010.01604.x
Berek J, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, Berchuck A; Society of Gynecologic Oncologists Clinical Practice Committee. Prophylactic and risk-reducing bilateral salpingo- oophorectomy: recommendations based on risk of ovarian cancer. Obstetrics and Gynecology. 2010;116(3):733. https://doi.org/10.1097/AOG.0b013e3181ec5fc1
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute. 2009;101(2):80-87. https://doi.org/10.1093/jnci/djn442
Morrow M, Mehrara B. Prophylactic mastectomy and the timing of breast reconstruction. British Journal of Surgery. 2009;96(1):1-2. https://doi.org/10.1002/bjs.6463
Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Journal of Clinical Oncology. 2002;20(5): 1260. https://doi.org/10.1200/JCO.2002.20.5.1260
Rebbeck T, Lynch T, Neuhausen S, Narod SA, Van’t Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England Journal of Medicine. 2002;346(21): 1616-1622. https://doi.org/10.1056/NEJMoa012158
Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. New England Journal of Medicine. 2002;346(21):1660-1662. https://doi.org/10.1056/NEJMed020044
Marchetti C, DeFelice F, Palaia I, Perniola G, Musella A, Musio D, Muzii L, Tombolini V, Panici PB. Risk-reducingsalpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014;14:150. https://doi.org/10.1186/s12905-014-0150-5
Zhordania KI, Payanidi YuG, Kalinicheva EV. A new paradigm in the etiology of serous ovarian cancer. Rossijskij bioterapevticheskij zhurnal. 2014;13(2):95-102. (In Russ.).
Leblanc E, Narducci F, Farre I, Peyrat JP, Taieb S, Adenis C, Vennin P. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecologic Oncology. 2011;121(3):472-476. https://doi.org/10.1016/j.ygyno.2011.02.012
McLaughlin J, Risch H, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. The Lancet. Oncology. 2007;8(1):26-34. https://doi.org/10.1016/S1470-2045(06)70983-4
Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, Bernard L, Maisonneuve P, Gandini S. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European Journal of Cancer. 2010;46(12):2275-2284. https://doi.org/10.1016/j.ejca.2010.04.018
King M, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B; National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1). Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251-2256. https://doi.org/10.1001/jama.286.18.2251
Vogel V, Costantino J, Wickerham D, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene. JAMA. 2006;295(23):2727-2741. https://doi.org/10.1001/jama.295.23.joc60074
Goss P, Ingle J, Alés-Martínez J, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine. 2011;364(25):2381-2391. https://doi.org/10.1056/NEJMoa1103507
Cuzick J, Sestak I, Forbes J, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A; IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo- controlled trial. Lancet. 2014;383(9922):1041-1048. https://doi.org/10.1016/S0140-6736(13)62292-8
Bardia A, Olson J, Vachon C, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, Cerhan JR. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Research and Treatment. 2011;126(1):149-155. https://doi.org/10.1007/s10549-010-1074-x
Takkouche B, Regueira-Méndez C, Etminan M. Breast Cancer and Use of Nonsteroidal Anti-inflammatory Drugs: A Meta-analysis. Journal of the National Cancer Institute. 2008;100(20):1439-1447. https://doi.org/10.1093/jnci/djn324
Friebel T, Domchek S, Rebbeck T. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. Journal of the National Cancer Institute. 2014;106(6): dju091. https://doi.org/10.1093/jnci/dju091
Terry M, Liao Y, Kast K, Antoniou AC, McDonald JA, Mooij TM, Engel C, Nogues C, Buecher B, Mari V, Moretta-Serra J, Gladieff L, Luporsi E, Barrowdale D, Frost D, Henderson A, Brewer C, Evans DG, Eccles D, Cook J, Ong KR, Izatt L, Ahmed M, Morrison PJ, Dommering CJ, Oosterwijk JC, Ausems MGEM, Kriege M, Buys SS, Andrulis IL, John EM, Daly M, Friedlander M, McLachlan SA, Osorio A, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Arver B, Olsson H, Schmutzler RK, Hopper JL, van Leeuwen FE, Goldgar D, Milne RL, Easton DF, Rookus MA, Andrieu N; EMBRACE, GENEPSO, BCFR, HEBON, kConFab and IBCCS. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women with BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum. 2018;2(4):pky078. https://doi.org/10.1093/jncics/pky078
Bracci M, Ciarapica V, Zabaleta M, Tartaglione MF, Pirozzi S, Giuliani L, Piva F, Valentino M, Ledda C, Rapisarda V, Stevens RG, Santarelli L. BRCA1 and BRCA2 Gene Expression: Diurnal Variability and Influence of Shift Work. Cancers. 2019;11(8):1146. https://doi.org/10.3390/cancers11081146
Pedro M, Baeza S, Escudero M, Dierssen-Sotos T, Gómez-Acebo I, Pollán M, Llorca J. Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment. 2015;149(2):525-536. https://doi.org/10.1007/s10549-015-3267-9